Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 112

1.

cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.

Chen Z, Li JL, Lin S, Cao C, Gimbrone NT, Yang R, Fu DA, Carper MB, Haura EB, Schabath MB, Lu J, Amelio AL, Cress WD, Kaye FJ, Wu L.

J Clin Invest. 2016 May 3. pii: 85250. doi: 10.1172/JCI85250. [Epub ahead of print]

PMID:
27140397
2.

A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.

Chen L, Engel BE, Welsh EA, Yoder SJ, Brantley SG, Chen DT, Beg AA, Cao C, Kaye FJ, Haura EB, Schabath MB, Cress WD.

J Thorac Oncol. 2016 Feb 23. pii: S1556-0864(16)00428-7. doi: 10.1016/j.jtho.2016.02.009. [Epub ahead of print]

3.

Treatment of ameloblastoma and ameloblastic carcinoma with radiotherapy.

Kennedy WR, Werning JW, Kaye FJ, Mendenhall WM.

Eur Arch Otorhinolaryngol. 2016 Jan 21. [Epub ahead of print]

PMID:
26796877
4.

Cisplatin loaded albumin mesospheres for lung cancer treatment.

Lee HY, Mohammed KA, Goldberg EP, Kaye F, Nasreen N.

Am J Cancer Res. 2015 Jan 15;5(2):603-15. eCollection 2015.

5.

Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.

François RA, Maeng K, Nawab A, Kaye FJ, Hochwald SN, Zajac-Kaye M.

J Natl Cancer Inst. 2015 May 12;107(8). pii: djv123. doi: 10.1093/jnci/djv123. Print 2015 Aug.

PMID:
25971297
6.

Re: a cancer theory kerfuffle can lead to new lines of research.

Kaye FJ.

J Natl Cancer Inst. 2015 Mar 11;107(5). pii: djv060. doi: 10.1093/jnci/djv060. No abstract available.

7.

A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets.

Gao R, Cao C, Zhang M, Lopez MC, Yan Y, Chen Z, Mitani Y, Zhang L, Zajac-Kaye M, Liu B, Wu L, Renne R, Baker HV, El-Naggar A, Kaye FJ.

Oncotarget. 2014 Dec 30;5(24):12528-42.

8.

Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.

Kaye FJ, Ivey AM, Drane WE, Mendenhall WM, Allan RW.

J Natl Cancer Inst. 2014 Dec 3;107(1):378. doi: 10.1093/jnci/dju378. Print 2015 Jan. No abstract available.

9.

Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer.

Cao C, Gao R, Zhang M, Amelio AL, Fallahi M, Chen Z, Gu Y, Hu C, Welsh EA, Engel BE, Haura EB, Cress WD, Wu L, Zajac-Kaye M, Kaye FJ.

J Natl Cancer Inst. 2014 Dec 1;107(1):358. doi: 10.1093/jnci/dju358. Print 2015 Jan.

10.

CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvement.

Amelio AL, Fallahi M, Schaub FX, Zhang M, Lawani MB, Alperstein AS, Southern MR, Young BM, Wu L, Zajac-Kaye M, Kaye FJ, Cleveland JL, Conkright MD.

Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3260-8. doi: 10.1073/pnas.1319176111. Epub 2014 Jul 28.

11.

Recurrent dermatophytosis (Majocchi granuloma) associated with chemotherapy-induced neutropenia.

Lourdes LS, Mitchell CL, Glavin FL, Schain DC, Kaye FJ.

J Clin Oncol. 2014 Sep 20;32(27):e92-4. No abstract available.

12.

Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.

Lee HS, Chen M, Kim JH, Kim WH, Ahn S, Maeng K, Allegra CJ, Kaye FJ, Hochwald SN, Zajac-Kaye M.

Int J Cancer. 2014 Jul 1;135(1):128-37. doi: 10.1002/ijc.28675. Epub 2014 Jan 6.

13.

Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer.

Lee HY, Mohammed KA, Kaye F, Sharma P, Moudgil BM, Clapp WL, Nasreen N.

Int J Nanomedicine. 2013;8:4481-94. doi: 10.2147/IJN.S41782. Epub 2013 Nov 21.

14.

hSETD1A regulates Wnt target genes and controls tumor growth of colorectal cancer cells.

Salz T, Li G, Kaye F, Zhou L, Qiu Y, Huang S.

Cancer Res. 2014 Feb 1;74(3):775-86. doi: 10.1158/0008-5472.CAN-13-1400. Epub 2013 Nov 18.

15.

Characterization of tumorigenic cell lines from the recurrence and lymph node metastasis of a human salivary mucoepidermoid carcinoma.

Warner KA, Adams A, Bernardi L, Nor C, Finkel KA, Zhang Z, McLean SA, Helman J, Wolf GT, Divi V, Queimado L, Kaye FJ, Castilho RM, Nör JE.

Oral Oncol. 2013 Nov;49(11):1059-66. doi: 10.1016/j.oraloncology.2013.08.004. Epub 2013 Sep 12.

16.

Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells.

Chen Z, Chen J, Gu Y, Hu C, Li JL, Lin S, Shen H, Cao C, Gao R, Li J, Ha PK, Kaye FJ, Griffin JD, Wu L.

Oncogene. 2014 Jul 17;33(29):3869-77. doi: 10.1038/onc.2013.348. Epub 2013 Aug 26.

PMID:
23975434
17.

Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.

Klorin G, Rozenblum E, Glebov O, Walker RL, Park Y, Meltzer PS, Kirsch IR, Kaye FJ, Roschke AV.

Cancer Genet. 2013 May;206(5):191-205. doi: 10.1016/j.cancergen.2013.04.006. Epub 2013 Jul 5.

18.

The 3rd Salivary Gland Tumor Workshop meeting report.

El-Naggar AK, Kaye FJ, Stenman G.

Head Neck. 2013 Aug;35(8):1057-60. doi: 10.1002/hed.23374. No abstract available.

PMID:
23677839
19.

Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.

Sukka-Ganesh B, Mohammed KA, Kaye F, Goldberg EP, Nasreen N.

BMC Cancer. 2012 Jul 23;12:309. doi: 10.1186/1471-2407-12-309.

20.

DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer.

Chen M, Shabashvili D, Nawab A, Yang SX, Dyer LM, Brown KD, Hollingshead M, Hunter KW, Kaye FJ, Hochwald SN, Marquez VE, Steeg P, Zajac-Kaye M.

Mol Cancer Ther. 2012 Feb;11(2):370-82. doi: 10.1158/1535-7163.MCT-11-0458. Epub 2011 Dec 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk